Skip to content

Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970
30.43 -0.58 -1.85%
Live - 5344 symbols - heartbeat 536s ago · 2026-10-08 07:54
Pre-market 30.20 -0.76%
After-hours 30.51 +0.26%
Market cap
2.39B
P/B
3.34
EPS
-3.90
Reader sentiment Are you bullish or bearish on CLDX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/7/20
  • Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $57
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70
    Market Newswire · 2026/7/23
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/7/22
  • Rating change
    LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $56
    Market Newswire · 2026/9/21
  • Rating change
    Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
    Market Newswire · 2026/6/15
  • Rating change
    Wolfe Research Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/6/15
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION), Celldex (CLDX) and Jazz Pharmaceuticals (JAZZ)
    TipRanks · 2026/6/18
  • Rating change
    Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $72
    Market Newswire · 2026/7/29
  • LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/9/28
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $100
    Market Newswire · 2026/9/23
  • Rating change
    LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
    Market Newswire · 2026/6/15
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $42 to $56
    Market Newswire · 2026/8/8
  • H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/10/5
  • Rating change
    Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/6/30
  • LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/10/3
  • Rating change
    H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/15
  • Rating change
    Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $50
    Market Newswire · 2026/9/10
  • Rating change
    A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $42 to $100
    Market Newswire · 2026/8/7
  • A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $88
    Market Newswire · 2026/9/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:54:55 · For reference only, not investment advice and not tailored to your situation.